The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Heat shock factor 1 (HSF1) drives cancer progression. Researchers discovered Homoharringtonine (HHT) as a potent HSF1 inhibitor, showing significant tumor regression in preclinical pancreatic cancer models.
Area Of Science
- Oncology
- Molecular Biology
- Drug Discovery
Background
- Heat shock factor 1 (HSF1) is crucial for cancer cell survival and progression.
- HSF1 amplification is linked to poor prognosis and treatment failure in various cancers, including pancreatic cancer (PC).
- Existing therapeutic strategies targeting HSF1 are limited by a lack of clinically validated small molecule inhibitors.
Purpose Of The Study
- To identify and validate a novel small molecule inhibitor targeting HSF1 for pancreatic cancer treatment.
- To evaluate the efficacy and mechanism of action of Homoharringtonine (HHT) as an HSF1 inhibitor.
Main Methods
- Development of a high-throughput screening system using a luciferase reporter assay for HSF1.
- In vitro evaluation of HHT's effect on PC cell viability.
- In vivo assessment of HHT's tumor regression efficacy in a subcutaneous xenograft model.
- Mechanistic studies to elucidate HHT's binding and inhibitory effects on HSF1.
Main Results
- Discovery of Homoharringtonine (HHT) as a potent HSF1 inhibitor through high-throughput screening.
- HHT selectively inhibited PC cell viability and demonstrated superior tumor regression compared to KRIBB11 in vivo.
- HHT directly binds to HSF1, suppressing its expression and downstream target genes.
- HHT showed potential in overcoming resistance associated with HSP90 inhibitors.
Conclusions
- Homoharringtonine (HHT) is a promising preclinical candidate as a direct HSF1 inhibitor for pancreatic cancer therapy.
- HHT's mechanism involves direct binding to HSF1, leading to inhibition of HSF1-mediated transcription.
- Further clinical investigation of HHT for pancreatic cancer is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...